Abstract
Chronic ischemia or pressure overload decreases thyroid hormone (TH) signaling and activates the fetal gene program in the heart. While these features are of physiologic importance in the developing heart, their respective roles in the postnatal heart are debated. Administration of TH can prevent the changes of the fetal gene program and rebuild the heart after an “index event” such as ischemia. TH affects cardiac remodeling by limiting reperfusion injury, and, at later states, by inducing distinct changes in cardiac chamber geometry in a time-dependent manner. Furthermore, administration of TH can convert pathologic to physiologic hypertrophy. These effects are the result of favorable cellular remodeling. While preliminary clinical studies provide encouraging results, the potential and efficacy of TH in the treatment of heart disease still await evaluation in large clinical trials.
Similar content being viewed by others
References
Swynghedauw B (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79:215–262
Pantos C, Mourouzis I, Saranteas T et al (2005) Thyroid hormone receptors alpha1 and beta1 are downregulated in the post-infarcted rat heart: consequences on the response to ischaemia–reperfusion. Basic Res Cardiol 100:422–432
Pantos C, Mourouzis I, Cokkinos DV (2007) Protection of the abnormal heart. Heart Fail Rev 12:319–330
Jopling C, Sleep E, Raya M et al (2010) Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature 464:606–609
Furlow JD, Yang HY, Hsu M et al (2004) Induction of larval tissue resorption in Xenopus laevis tadpoles by the thyroid hormone receptor agonist GC-1. J Biol Chem 279:26555–26562
Heikkila JJ (2010) Heat shock protein gene expression and function in amphibian model systems. Comp Biochem Physiol A Mol Integr Physiol 156:19–33
Morvan-Dubois G, Demeneix BA, Sachs LM (2008) Xenopus laevis as a model for studying thyroid hormone signalling: from development to metamorphosis. Mol Cell Endocrinol 293:71–79
Kress E, Samarut J, Plateroti M (2009) Thyroid hormones and the control of cell proliferation or cell differentiation: paradox or duality? Mol Cell Endocrinol 313:36–49
Mai W, Janier MF, Allioli N et al (2004) Thyroid hormone receptor alpha is a molecular switch of cardiac function between fetal and postnatal life. Proc Natl Acad Sci USA 101:10332–10337
Pantos C, Xinaris C, Mourouzis I et al (2008) Thyroid hormone receptor alpha 1: a switch to cardiac cell “metamorphosis”? J Physiol Pharmacol 59:253–269
De Groot LJ (1999) Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab 84:151–164
Hennemann G (2005) Notes on the history of cellular uptake and deiodination of thyroid hormone. Thyroid 15:753–756
Bianco AC, Salvatore D, Gereben B et al (2002) Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38–89
Bianco AC, Kim BW (2006) Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 116:2571–2579
Lanni A, Moreno M, Lombardi A et al (2005) 3,5-Diiodo-l-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. FASEB J 19:1552–1554
Scanlan TS, Suchland KL, Hart ME et al (2004) 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 10:638–642
Nicoll JB, Gwinn BL, Iwig JS et al (2003) Compartment-specific phosphorylation of rat thyroid hormone receptor alpha1 regulates nuclear localization and retention. Mol Cell Endocrinol 205:65–77
Kinugawa K, Yonekura K, Ribeiro RC et al (2001) Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res 89:591–598
Flamant F, Samarut J (2003) Thyroid hormone receptors: lessons from knockout and knock-in mutant mice. Trends Endocrinol Metab 14:85–90
Kinugawa K, Jeong MY, Bristow MR et al (2005) Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase. Mol Endocrinol 19:1618–1628
Pantos C, Mourouzis I, Malliopoulou V et al (2005) Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor alpha1. Thyroid 15:16–23
Pantos C, Mourouzis I, Paizis I et al (2007) Pharmacological inhibition of TRalpha1 receptor potentiates the thyroxine effect on body weight reduction in rats: potential therapeutic implications in controlling body weight. Diabetes Obes Metab 9:136–138
Gullberg H, Rudling M, Salto C et al (2002) Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice. Mol Endocrinol 16:1767–1777
Forrest D, Hanebuth E, Smeyne RJ et al (1996) Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue-specific modulation of receptor function. EMBO J 15:3006–3015
Tavi P, Sjogren M, Lunde PK et al (2005) Impaired Ca2+ handling and contraction in cardiomyocytes from mice with a dominant negative thyroid hormone receptor alpha1. J Mol Cell Cardiol 38:655–663
Luidens MK, Mousa SA, Davis FB et al (2010) Thyroid hormone and angiogenesis. Vascul Pharmacol 52:142–145
Wikstrom L, Johansson C, Salto C et al (1998) Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. EMBO J 17:455–461
Venero C, Guadano-Ferraz A, Herrero AI et al (2005) Anxiety, memory impairment, and locomotor dysfunction caused by a mutant thyroid hormone receptor alpha1 can be ameliorated by T3 treatment. Genes Dev 19:2152–2163
Kress E, Rezza A, Nadjar J et al (2008) The thyroid hormone receptor-alpha (TRalpha) gene encoding TRalpha1 controls deoxyribonucleic acid damage-induced tissue repair. Mol Endocrinol 22:47–55
Belakavadi M, Saunders J, Weisleder N et al (2010) Repression of cardiac phospholamban gene expression is mediated by thyroid hormone receptor-{alpha}1 and involves targeted covalent histone modifications. Endocrinology 151:2946–2956
Esaki T, Suzuki H, Cook M et al (2004) Cardiac glucose utilization in mice with mutated alpha- and beta-thyroid hormone receptors. Am J Physiol Endocrinol Metab 287:E1149–E1153
White P, Burton KA, Fowden AL et al (2001) Developmental expression analysis of thyroid hormone receptor isoforms reveals new insights into their essential functions in cardiac and skeletal muscles. FASEB J 15:1367–1376
Chassande O (2003) Do unliganded thyroid hormone receptors have physiological functions? J Mol Endocrinol 31:9–20
Li Q, Sachs L, Shi YB et al (1999) Modification of chromatin structure by the thyroid hormone receptor. Trends Endocrinol Metab 10:157–164
Zhang J, Lazar MA (2000) The mechanism of action of thyroid hormones. Annu Rev Physiol 62:439–466
Flamant F, Poguet AL, Plateroti M et al (2002) Congenital hypothyroid Pax8(−/−) mutant mice can be rescued by inactivating the TRalpha gene. Mol Endocrinol 16:24–32
Morte B, Manzano J, Scanlan T et al (2002) Deletion of the thyroid hormone receptor alpha 1 prevents the structural alterations of the cerebellum induced by hypothyroidism. Proc Natl Acad Sci USA 99:3985–3989
Kaneshige M, Suzuki H, Kaneshige K et al (2001) A targeted dominant negative mutation of the thyroid hormone alpha 1 receptor causes increased mortality, infertility, and dwarfism in mice. Proc Natl Acad Sci USA 98:15095–15100
Tinnikov A, Nordstrom K, Thoren P et al (2002) Retardation of post-natal development caused by a negatively acting thyroid hormone receptor alpha1. EMBO J 21:5079–5087
Cody V, Davis PJ, Davis FB (2007) Molecular modeling of the thyroid hormone interactions with alpha v beta 3 integrin. Steroids 72:165–170
Hiroi Y, Kim HH, Ying H et al (2006) Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 103:14104–14109
Alpert NR, Brosseau C, Federico A et al (2002) Molecular mechanics of mouse cardiac myosin isoforms. Am J Physiol Heart Circ Physiol 283:H1446–H1454
Pantos C, Mourouzis I, Xinaris C et al (2008) Thyroid hormone and “cardiac metamorphosis”: potential therapeutic implications. Pharmacol Ther 118:277–294
Pantos C, Xinaris C, Mourouzis I et al (2008) TNF-alpha administration in neonatal cardiomyocytes is associated with differential expression of thyroid hormone receptors: a response prevented by T3. Horm Metab Res 40:731–734
Simonides WS, Mulcahey MA, Redout EM et al (2008) Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J Clin Invest 118:975–983
Ojamaa K, Kenessey A, Shenoy R et al (2000) Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat. Am J Physiol Endocrinol Metab 279:E1319–E1324
Olivares EL, Marassi MP, Fortunato RS et al (2007) Thyroid function disturbance and type 3 iodothyronine deiodinase induction after myocardial infarction in rats a time course study. Endocrinology 148:4786–4792
Pol CJ, van Deel ED, Muller A et al (2008) Left ventricular myocardial infarction in mice induces sustained cardiac deiodinase type III activity. J Mol Cell Cardiol 44:722–723
Wassen FW, Schiel AE, Kuiper GG et al (2002) Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology 143:2812–2815
Pantos C, Mourouzis I, Xinaris C et al (2007) Time-dependent changes in the expression of thyroid hormone receptor {alpha}1 in the myocardium after acute myocardial infarction: possible implications in cardiac remodelling. Eur J Endocrinol 156:415–424
Pantos C, Mourouzis I, Galanopoulos G et al (2010) Thyroid hormone receptor α1 down-regulation in postischemic heart failure progression: the potential role of tissue hypothyroidism. Horm Metab Res (in press). doi:10.1055/s-0030-1255035
Pantos C, Malliopoulou V, Mourouzis I et al (2003) Propylthiouracil-induced hypothyroidism is associated with increased tolerance of the isolated rat heart to ischaemia–reperfusion. J Endocrinol 178:427–435
Mourouzis I, Dimopoulos A, Saranteas T et al (2009) Ischemic preconditioning fails to confer additional protection against ischemia-reperfusion injury in the hypothyroid rat heart. Physiol Res 58:29–38
Pantos C, Mourouzis I, Tsagoulis N et al (2009) Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction. J Physiol Pharmacol 60:49–56
Kalofoutis C, Galanopoulos G, Mourouzis I et al (2010) Post-ischemic cardiac remodeling is accelerated in diabetic rats due to tissue hypothyroidism. Journal of Molecular and Cellular Cardiology 48:S133 (abstract)
Trivieri MG, Oudit GY, Sah R et al (2006) Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci USA 103:6043–6048
Belke DD, Gloss B, Swanson EA et al (2007) Adeno-associated virus-mediated expression of thyroid hormone receptor isoforms-alpha1 and -beta1 improves contractile function in pressure overload-induced cardiac hypertrophy. Endocrinology 148:2870–2877
Khalife WI, Tang YD, Kuzman JA et al (2005) Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289:H2409–H2415
Ferrari R (1999) The role of TNF in cardiovascular disease. Pharmacol Res 40:97–105
Chung ES, Packer M, Lo KH et al (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107:3133–3140
Shannon R, Chaudhry M (2006) Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J 152:842–850
Xiao L, Pimental DR, Amin JK et al (2001) MEK1/2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 33:779–787
Barron AJ, Finn SG, Fuller SJ (2003) Chronic activation of extracellular-signal-regulated protein kinases by phenylephrine is required to elicit a hypertrophic response in cardiac myocytes. Biochem J 371:71–79
Proud CG (2004) Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 63:403–413
Dorn GW II, Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527–537
Miki T, Miura T, Tanno M et al (2007) Impairment of cardioprotective PI3K-Akt signaling by post-infarct ventricular remodeling is compensated by an ERK-mediated pathway. Basic Res Cardiol 102:163–170
Kehat I, Molkentin JD (2010) Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci 1188:96–102
Weigel NL (1996) Steroid hormone receptors and their regulation by phosphorylation. Biochem J 319(Pt 3):657–667
Pantos C, Mourouzis I, Markakis K et al (2008) Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. Basic Res Cardiol 103:308–318
Frost RJ, van Rooij E (2010) miRNAs as therapeutic targets in ischemic heart disease. J Cardiovasc Transl Res 3:280–289
van Rooij E, Sutherland LB, Qi X et al (2007) Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316:575–579
Callis TE, Pandya K, Seok HY et al (2009) MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 119:2772–2786
Pantos C, Mourouzis I, Markakis K et al (2007) Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats. Eur J Cardiothorac Surg 32:333–339
Hambleton M, Hahn H, Pleger ST et al (2006) Pharmacological- and gene therapy-based inhibition of protein kinase C alpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 114:574–582
Scruggs SB, Walker LA, Lyu T et al (2006) Partial replacement of cardiac troponin I with a non-phosphorylatable mutant at serines 43/45 attenuates the contractile dysfunction associated with PKCepsilon phosphorylation. J Mol Cell Cardiol 40:465–473
Kim YK, Suarez J, Hu Y et al (2006) Deletion of the inducible 70-kDa heat shock protein genes in mice impairs cardiac contractile function and calcium handling associated with hypertrophy. Circulation 113:2589–2597
Lembcke A, Dushe S, Dohmen PM et al (2006) Early and late effects of passive epicardial constraint on left ventricular geometry: ellipsoidal re-shaping confirmed by electron-beam computed tomography. J Heart Lung Transplant 25:90–98
Pantos C, Xinaris C, Mourouzis I et al (2007) Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: potential therapeutic implications in reversing cardiac remodeling? Mol Cell Biochem 297:65–72
Kenessey A, Ojamaa K (2006) Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem 281:20666–20672
Ziegelhoffer-Mihalovicova B, Briest W, Baba HA et al (2003) The expression of mRNA of cytokines and of extracellular matrix proteins in triiodothyronine-treated rat hearts. Mol Cell Biochem 247:61–68
Yao J, Eghbali M (1992) Decreased collagen gene expression and absence of fibrosis in thyroid hormone-induced myocardial hypertrophy. Response of cardiac fibroblasts to thyroid hormone in vitro. Circ Res 71:831–839
Wong K, Boheler KR, Petrou M et al (1997) Pharmacological modulation of pressure-overload cardiac hypertrophy: changes in ventricular function, extracellular matrix, and gene expression. Circulation 96:2239–2246
Wang X, Zheng W, Christensen LP et al (2003) DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. Am J Physiol Heart Circ Physiol 284:H613–H618
Bergh JJ, Lin HY, Lansing L et al (2005) Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146:2864–2871
Mousa SA, O’Connor L, Davis FB et al (2006) Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology 147:1602–1607
Mousa SA, Davis FB, Mohamed S et al (2006) Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 25:407–413
Mousa SA, O’Connor LJ, Bergh JJ et al (2005) The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 46:356–360
Makino A, Suarez J, Wang H et al (2009) Thyroid hormone receptor-beta is associated with coronary angiogenesis during pathological cardiac hypertrophy. Endocrinology 150:2008–2015
Sirlak M, Yazicioglu L, Inan MB et al (2004) Oral thyroid hormone pretreatment in left ventricular dysfunction. Eur J Cardiothorac Surg 26:720–725
Pantos CI, Tzilalis V, Giannakakis S et al (2001) Phenylephrine induced aortic vasoconstriction is attenuated in hyperthyroid rats. Int Angiol 20:181–186
Pappas M, Mourouzis K, Karageorgiou H et al (2009) Thyroid hormone modulates the responsiveness of rat aorta to a1-adrenergic stimulation: an effect due to increased activation of b2-adrenergic signaling. Int Angiol 28:474–478
Pantos C, Mourouzis I, Cokkinos DV (2006) Myocardial ischemia: basic concepts. In: Cokkinos DV, Pantos C, Heusch G, Taegtmeyer H (eds) Myocardial ischemia: from mechanisms to therapeutic potentials. Springer, New York, pp 11–77
Skyschally A, van Caster P, Iliodromitis EK et al (2009) Ischemic postconditioning: experimental models and protocol algorithms. Basic Res Cardiol 104:469–483
Heusch G, Boengler K, Schulz R (2010) Inhibition of mitochondrial permeability transition pore opening: the Holy Grail of cardioprotection. Basic Res Cardiol 105:151–154
Ovize M, Baxter GF, Di Lisa F et al (2010) Postconditioning and protection from reperfusion injury: where do we stand?: position paper from the working group of cellular biology of the heart of the european society of cardiology. Cardiovasc Res. doi:10.1093/cvr/cvq1129
Klemperer JD, Zelano J, Helm RE et al (1995) Triiodothyronine improves left ventricular function without oxygen wasting effects after global hypothermic ischemia. J Thorac Cardiovasc Surg 109:457–465
Walker JD, Crawford FA Jr, Spinale FG (1995) 3,5,3′ Triiodo-l-thyronine pretreatment with cardioplegic arrest and chronic left ventricular dysfunction. Ann Thorac Surg 60:292–299
Liu Q, Clanachan AS, Lopaschuk GD (1998) Acute effects of triiodothyronine on glucose and fatty acid metabolism during reperfusion of ischemic rat hearts. Am J Physiol 275:E392–E399
Spinale FG (1999) Cellular and molecular therapeutic targets for treatment of contractile dysfunction after cardioplegic arrest. Ann Thorac Surg 68:1934–1941
Zinman T, Shneyvays V, Tribulova N et al (2006) Acute, nongenomic effect of thyroid hormones in preventing calcium overload in newborn rat cardiocytes. J Cell Physiol 207:220–231
Buser PT, Wikman-Coffelt J, Wu ST et al (1990) Postischemic recovery of mechanical performance and energy metabolism in the presence of left ventricular hypertrophy. A 31P-MRS study. Circ Res 66:735–746
Pantos CI, Malliopoulou VA, Mourouzis IS et al (2001) Long-term thyroxine administration increases heat stress protein-70 mRNA expression and attenuates p38 MAP kinase activity in response to ischaemia. J Endocrinol 170:207–215
Pantos CI, Malliopoulou VA, Mourouzis IS et al (2002) Long-term thyroxine administration protects the heart in a pattern similar to ischemic preconditioning. Thyroid 12:325–329
Pantos C, Malliopoulou V, Mourouzis I et al (2003) Thyroxine pretreatment increases basal myocardial heat-shock protein 27 expression and accelerates translocation and phosphorylation of this protein upon ischaemia. Eur J Pharmacol 478:53–60
Pantos C, Malliopoulou V, Mourouzis I et al (2003) Involvement of p38 MAPK and JNK in heat stress-induced cardioprotection. Basic Res Cardiol 98:158–164
Kuzman JA, Gerdes AM, Kobayashi S et al (2005) Thyroid hormone activates Akt and prevents serum starvation-induced cell death in neonatal rat cardiomyocytes. J Mol Cell Cardiol 39:841–844
Pantos C, Malliopoulou V, Mourouzis I et al (2006) Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70. Horm Metab Res 38:308–313
Pantos CI, Mourouzis IS, Tzeis SM et al (2000) Propranolol diminishes cardiac hypertrophy but does not abolish acceleration of the ischemic contracture in hyperthyroid hearts. J Cardiovasc Pharmacol 36:384–389
Pantos CI, Cokkinos DD, Tzeis SM et al (1999) Hyperthyroidism is associated with preserved preconditioning capacity but intensified and accelerated ischaemic contracture in rat heart. Basic Res Cardiol 94:254–260
Pantos C, Paizis I, Mourouzis I et al (2005) Blockade of angiotensin II type 1 receptor diminishes cardiac hypertrophy, but does not abolish thyroxin-induced preconditioning. Horm Metab Res 37:500–504
Speechly-Dick ME, Mocanu MM, Yellon DM (1994) Protein kinase C. Its role in ischemic preconditioning in the rat. Circ Res 75:586–590
Zhao J, Renner O, Wightman L et al (1998) The expression of constitutively active isotypes of protein kinase C to investigate preconditioning. J Biol Chem 273:23072–23079
Maizels ET, Peters CA, Kline M et al (1998) Heat-shock protein-25/27 phosphorylation by the delta isoform of protein kinase C. Biochem J 332(Pt 3):703–712
Pantos C, Malliopoulou V, Paizis I et al (2003) Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. Mol Cell Biochem 242:173–180
Martin JL, Mestril R, Hilal-Dandan R et al (1997) Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 96:4343–4348
Venditti P, Di Meo S (2006) Thyroid hormone-induced oxidative stress. Cell Mol Life Sci 63:414–434
Downey JM, Davis AM, Cohen MV (2007) Signaling pathways in ischemic preconditioning. Heart Fail Rev 12:181–188
Novitzky D, Cooper DK, Swanepoel A (1989) Inotropic effect of triiodothyronine (T3) in low cardiac output following cardioplegic arrest and cardiopulmonary bypass: an initial experience in patients undergoing open heart surgery. Eur J Cardiothorac Surg 3:140–145
Dyke CM, Yeh T Jr, Lehman JD et al (1991) Triiodothyronine-enhanced left ventricular function after ischemic injury. Ann Thorac Surg 52:14–19
Novitzky D, Matthews N, Shawley D et al (1991) Triiodothyronine in the recovery of stunned myocardium in dogs. Ann Thorac Surg 51:10–16; discussion 16–17
Holland FW II, Brown PS Jr, Clark RE (1992) Acute severe postischemic myocardial depression reversed by triiodothyronine. Ann Thorac Surg 54:301–305
Dyke CM, Ding M, Abd-Elfattah AS et al (1993) Effects of triiodothyronine supplementation after myocardial ischemia. Ann Thorac Surg 56:215–222
Kadletz M, Mullen PG, Ding M et al (1994) Effect of triiodothyronine on postischemic myocardial function in the isolated heart. Ann Thorac Surg 57:657–662
Klemperer JD, Klein I, Gomez M et al (1995) Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 333:1522–1527
Ranasinghe AM, Quinn DW, Pagano D et al (2006) Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting. Circulation 114:I245–I250
Pantos C, Mourouzis I, Tzeis S et al (2003) Dobutamine administration exacerbates postischaemic myocardial dysfunction in isolated rat hearts: an effect reversed by thyroxine pretreatment. Eur J Pharmacol 460:155–161
Chen YF, Kobayashi S, Chen J et al (2008) Short term triiodo-l-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol 44:180–187
Forini F, Lionetti V, Ardehali H et al (2010) Early long-term L-T3 replacement rescues mitochondria and prevents ischemic cardiac remodeling in rats. J Cell Mol Med (in press). doi:10.1111/j.1582-4934.2010.01014
Marin-Garcia J (2010) Thyroid hormone and myocardial mitochondrial biogenesis. Vascul Pharmacol 52:120–130
Chang KC, Figueredo VM, Schreur JH et al (1997) Thyroid hormone improves function and Ca2+ handling in pressure overload hypertrophy. Association with increased sarcoplasmic reticulum Ca2+-ATPase and alpha-myosin heavy chain in rat hearts. J Clin Invest 100:1742–1749
Thomas TA, Kuzman JA, Anderson BE et al (2005) Thyroid hormones induce unique and potentially beneficial changes in cardiac myocyte shape in hypertensive rats near heart failure. Am J Physiol Heart Circ Physiol 288:H2118–H2122
Ito K, Kagaya Y, Shimokawa H (2010) Thyroid hormone and chronically unloaded hearts. Vascul Pharmacol 52:138–141
Minatoya Y, Ito K, Kagaya Y et al (2007) Depressed contractile reserve and impaired calcium handling of cardiac myocytes from chronically unloaded hearts are ameliorated with the administration of physiological treatment dose of T3 in rats. Acta Physiol (Oxf) 189:221–231
Klein I, Ojamaa K (2001) Thyroid hormone-targeting the heart. Endocrinology 142:11–12
Abo-Zenah HA, Shoeb SA, Sabry AA et al (2008) Relating circulating thyroid hormone concentrations to serum interleukins-6 and 10 in association with non-thyroidal illnesses including chronic renal insufficiency. BMC Endocr Disord 8:1–7
Kimura T, Kanda T, Kotajima N et al (2000) Involvement of circulating interleukin-6 and its receptor in the development of euthyroid sick syndrome in patients with acute myocardial infarction. Eur J Endocrinol 143:179–184
Eber B, Schumacher M, Langsteger W et al (1995) Changes in thyroid hormone parameters after acute myocardial infarction. Cardiology 86:152–156
Holland FW II, Brown PS Jr, Weintraub BD et al (1991) Cardiopulmonary bypass and thyroid function: a “euthyroid sick syndrome”. Ann Thorac Surg 52:46–50
Friberg L, Werner S, Eggertsen G et al (2002) Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med 162:1388–1394
Iervasi G, Pingitore A, Landi P et al (2003) Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 107:708–713
Pingitore A, Iervasi G, Barison A et al (2006) Early activation of an altered thyroid hormone profile in asymptomatic or mildly symptomatic idiopathic left ventricular dysfunction. J Card Fail 12:520–526
Pantos C, Dritsas A, Mourouzis I et al (2007) Thyroid hormone is a critical determinant of myocardial performance in patients with heart failure: potential therapeutic implications. Eur J Endocrinol 157:515–520
Moruzzi P, Doria E, Agostoni PG et al (1994) Usefulness of l-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol 73:374–378
Moruzzi P, Doria E, Agostoni PG (1996) Medium-term effectiveness of l-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med 101:461–467
Pingitore A, Galli E, Barison A et al (2008) Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 93:1351–1358
Liu Z, Wu J, Zhang YY et al (2009) Therapeutic effect of low-dose thyroxin in elderly patients with refractory heart failure and euthyroid sick syndrome. Nan Fang Yi Ke Da Xue Xue Bao 29:1848–1850
Goldman S, McCarren M, Morkin E et al (2009) DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation 119:3093–3100
Pantos C, Mourouzis I, Saranteas T et al (2009) Thyroid hormone improves postischaemic recovery of function while limiting apoptosis: a new therapeutic approach to support hemodynamics in the setting of ischaemia–reperfusion? Basic Res Cardiol 104:69–77
Acknowledgments
We thank the S. Niarchos Foundation for support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pantos, C., Mourouzis, I. & Cokkinos, D.V. New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider?. Heart Fail Rev 16, 79–96 (2011). https://doi.org/10.1007/s10741-010-9185-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-010-9185-3